Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Monday 28 February, 2022

C4X Discovery

Exercise of Options, Issue of Equity and TVR

RNS Number : 0970D
C4X Discovery Holdings PLC
28 February 2022
 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")  

Exercise of Options, Issue of Equity and Total Voting Rights

28 February 2022  - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces  it has issued  319,275 ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise of options by two employees of the Company.

 

Admission and Total Voting Rights

Application has been made for the 319,275 New Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 4 March 2022. The New Ordinary Shares will rank pari passu with the existing ordinary shares. 

 

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued share capital now consists of 229,231,972 ordinary shares. Accordingly, the figure of 229,231,972 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Contacts

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977

 

 



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

 

Rupert Dearden (Corporate Broking)

 

 




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRZZGZZNRNGZZM

a d v e r t i s e m e n t